Bli medlem
Bli medlem

Du är här

2021-06-17

Scandinavian ChemoTech receives approval from the European Patent Office

Scandinavian ChemoTech AB announces today that the Company has received approval from the European Patent Office. The final injunction for this patent application was announced in a press release on the 3[d ]of February 2021. The examiner announces that the approval will be published 7[th] of July 2021.

The patent covers a specially developed electrode as well as unique dynamic properties, which already exist in the TSE platform, intended to treat tumours without damaging important parts of organs and tissues such as nerve pathways and blood vessels. This is of utmost importance in the treatment of, among other things, the spine and prostate.

This innovation provides improved pain control when using the Company's DEEPC™ (Dynamic Electro Enhanced Pain Control) device for IQwave™, for the delivery of electrical pulses to the desired body part.

"A few weeks ago, ChemoTech received CE marking for its medical technology product and system for cancer treatment. It is very gratifying to now also have this EU patent approved, which shows the wide technical range of ChemoTech's TSE platform. We are now expanding the patent protection to also include pain relief, which is a very important part of cancer treatment. This approval gives ChemoTech's human and veterinary operations both the important protection needed for both the commercial establishment in the EU and that it attracts potential partners for distribution and / or licensing agreements. " - says Mohan Frick, CEO and author of this patent together with Prof B Persson

For more information, please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

info@chemotech.se

Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.